Literature DB >> 20357133

The PANSS should be rescaled.

Stefan Leucht1, Werner Kissling, John M Davis.   

Abstract

Mesh:

Substances:

Year:  2010        PMID: 20357133      PMCID: PMC2879684          DOI: 10.1093/schbul/sbq016

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


× No keyword cloud information.
  7 in total

1.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

Review 2.  Definitions of response and remission in schizophrenia: recommendations for their use and their presentation.

Authors:  S Leucht; J M Davis; R R Engel; W Kissling; J M Kane
Journal:  Acta Psychiatr Scand Suppl       Date:  2009

3.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

4.  The brief psychiatric rating scale: effect of scaling system on clinical response assessment.

Authors:  P A Thompson; P F Buckley; H Y Meltzer
Journal:  J Clin Psychopharmacol       Date:  1994-10       Impact factor: 3.153

Review 5.  Remission in schizophrenia: proposed criteria and rationale for consensus.

Authors:  Nancy C Andreasen; William T Carpenter; John M Kane; Robert A Lasser; Stephen R Marder; Daniel R Weinberger
Journal:  Am J Psychiatry       Date:  2005-03       Impact factor: 18.112

6.  Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs.

Authors:  Stefan Leucht; John M Davis; Rolf R Engel; John M Kane; Stefan Wagenpfeil
Journal:  Neuropsychopharmacology       Date:  2007-02-07       Impact factor: 7.853

7.  A new depression scale designed to be sensitive to change.

Authors:  S A Montgomery; M Asberg
Journal:  Br J Psychiatry       Date:  1979-04       Impact factor: 9.319

  7 in total
  19 in total

1.  Converting positive and negative symptom scores between PANSS and SAPS/SANS.

Authors:  Theo G M van Erp; Adrian Preda; Dana Nguyen; Lawrence Faziola; Jessica Turner; Juan Bustillo; Aysenil Belger; Kelvin O Lim; Sarah McEwen; James Voyvodic; Daniel H Mathalon; Judith Ford; Steven G Potkin
Journal:  Schizophr Res       Date:  2013-12-11       Impact factor: 4.939

Review 2.  Is the PANSS used correctly? a systematic review.

Authors:  Michael Obermeier; Rebecca Schennach-Wolff; Sebastian Meyer; Hans-Jürgen Möller; Michael Riedel; Daniela Krause; Florian Seemüller
Journal:  BMC Psychiatry       Date:  2011-07-18       Impact factor: 3.630

3.  How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials.

Authors:  Myrto T Samara; Adriani Nikolakopoulou; Georgia Salanti; Stefan Leucht
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

4.  The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.

Authors:  E Sacchetti; C Magri; A Minelli; P Valsecchi; M Traversa; S Calza; A Vita; M Gennarelli
Journal:  Pharmacogenomics J       Date:  2016-02-09       Impact factor: 3.550

5.  Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.

Authors:  Haya Ascher-Svanum; Fangyi Zhao; Holland C Detke; Allen W Nyhuis; Anthony H Lawson; Virginia L Stauffer; William Montgomery; Michael M Witte; David P McDonnell
Journal:  BMC Psychiatry       Date:  2011-09-23       Impact factor: 3.630

Review 6.  Mirtazapine adjunct for people with schizophrenia.

Authors:  Luke A Perry; Dhruvesh Ramson; Suzanne Stricklin
Journal:  Cochrane Database Syst Rev       Date:  2018-05-26

7.  Schizophrenia gene expression profile reverted to normal levels by antipsychotics.

Authors:  Benedicto Crespo-Facorro; Carlos Prieto; Jesus Sainz
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

8.  Dose-response meta-analysis of differences in means.

Authors:  Alessio Crippa; Nicola Orsini
Journal:  BMC Med Res Methodol       Date:  2016-08-02       Impact factor: 4.615

9.  Effectiveness of Electroconvulsive Therapy Augmentation on Clozapine-Resistant Schizophrenia.

Authors:  Hye Sung Kim; Se Hyun Kim; Nam Young Lee; Tak Youn; Jeoung Hyuk Lee; Seunghyun Chung; Yong Sik Kim; In Won Chung
Journal:  Psychiatry Investig       Date:  2016-12-29       Impact factor: 2.505

10.  Association between DRD2 and ANKK1 polymorphisms with the deficit syndrome in schizophrenia.

Authors:  Anna Michalczyk; Justyna Pełka-Wysiecka; Jolanta Kucharska-Mazur; Michał Wroński; Błażej Misiak; Jerzy Samochowiec
Journal:  Ann Gen Psychiatry       Date:  2020-06-17       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.